Concordance Rate between Clinicians and Watson for Oncology among Patients with Advanced Gastric Cancer: Early, Real-World Experience in Korea

Table 1

Baseline characteristics of the patients with advanced gastric cancer (n = 65).

Characteristic	n ()
Age, years	61.0 ± 11.7, 60.0 (52.0–71.0)
Gender (M: F)	44: 21
BMI	21.4 ± 3.5, 21.3 (18.6–23.8)
Chemotherapy
First	51 (78.5%)
Second	10 (15.4%)
Third	4 (6.2%)
Adjuvant chemotherapy	23 (47.9)
Palliative chemotherapy	25 (52.1)
R resection
R0	41 (63.1)
R1	2 (3.1)
R2	2 (3.1)
HER2+	9 (13.8)
Prior therapy
Surgery	52 (80.0)
Chemotherapy	12 (18.5)
Surgery and chemotherapy	1 (1.5)
Stage
IIA	9 (13.8)
IIB	12 (18.5)
IIIA	5 (7.7)
IIIB	5 (7.7)
IIIC	9 (13.8)
IV	25 (38.5)
Death	6 (9.2)
Performance
ECOG 0	14 (21.5)
ECOG 1	45 (69.2)
ECOG 2	6 (9.2)

BMI, body mass index; HER2/neu, human epidermal growth factor receptor; ECOG,Eastern Cooperative Oncology Group.